Karyomegalic Interstitial Nephritis (KIN): A Comprehensive Disease Characteristics Report

Disease: Karyomegalic Interstitial Nephritis (KIN) Suggested MONDO: MONDO:0011980 (karyomegalic interstitial nephritis) · OMIM: 614817 (Interstitial nephritis, karyomegalic; KMIN) · Orphanet: ORPHA:401996 · Gene: FAN1 (FANCD2/FANCI-associated nuclease 1), HGNC:29170, locus 15q13.3 · Category: Mendelian (autosomal recessive), with acquired/toxin-associated phenocopies ICD-10: N11.9 (chronic tubulo-interstitial nephritis, unspecified) as closest proxy · MeSH: "Nephritis, Interstitial" (D009395) as parent; karyomegalic interstitial nephritis has no unique MeSH descriptor Evidence base: 44 papers reviewed; 10 confirmed findings

Summary

Karyomegalic interstitial nephritis (KIN) is a rare, autosomal-recessive chronic tubulointerstitial kidney disease defined histologically by grossly enlarged, hyperchromatic, pleomorphic nuclei ("karyomegaly") in renal tubular epithelial cells, accompanied by interstitial inflammation, tubular atrophy, and progressive interstitial fibrosis. It presents as asymptomatic, slowly progressive renal failure — typically in the second to fourth decade of life — often with recurrent respiratory infections and non-specifically elevated liver enzymes, culminating in end-stage renal disease (ESRD). It is genetically caused by biallelic loss-of-function variants in FAN1, a structure-specific DNA nuclease. Landmark exome sequencing established this link: "By exome sequencing, we identified mutations in FAN1 as a cause of karyomegalic interstitial nephritis (KIN), a disorder that serves as a model for renal fibrosis" (PMID: 22772369).

Mechanistically, FAN1 has two separable genome-maintenance activities: (1) unhooking/repair of DNA interstrand cross-links (ICLs), which is independent of the Fanconi anemia (FA) pathway and redundant with the exonuclease SNM1A; and (2) protection and restraint of stalled DNA replication forks, recruited via ubiquitylated PCNA and ubiquitylated FANCD2. This investigation concluded that fork protection — not merely ICL repair — is plausibly the more KIN-relevant function, because its loss produces chromosome abnormalities and genome instability even without exogenous cross-links. In tubular cells, unresolved replication stress and DNA damage lead to inhibited mitosis, endoreduplication and polyploidy (documented by DNA-ploidy flow cytometry and absent proliferation markers), producing the diagnostic karyomegaly, and downstream to tubular injury, fibrosis, and CKD. Environmental genotoxins — the mycotoxin ochratoxin A, alkylating/chemotherapeutic agents (carboplatin, ifosfamide, cisplatin), the antibody-drug conjugate brentuximab, and the JAK inhibitor ruxolitinib — can act as "second hits" or, in some cases, produce a FAN1-negative acquired phenocopy.

KIN is a systemic disorder: karyomegalic nuclei have been documented at autopsy in brain, thyroid, lung, esophagus, arteries, skin, duodenum, and liver. There is no disease-specific therapy; management is supportive and preventive (nephroprotection, avoidance of genotoxins, dialysis, and kidney transplantation). Transplantation carries a distinctive risk: two patients in an early series died soon after transplant from overwhelming respiratory sepsis, and heterozygous-carrier related donors must be avoided (recurrent/donor-derived KIN has occurred in allografts). FAN1 is pleiotropic beyond the kidney, contributing to hereditary colorectal cancer predisposition and acting as one of the strongest DNA-repair modifiers of age-of-onset in CAG-repeat expansion disorders such as Huntington's disease.

Section 1 — Disease Information

Overview. KIN is "an uncommon autosomal recessive disease, which is characterized by enlarged and hyperchromatic nuclei of the renal tubular epithelial cells... associated with mutations in Fanconi anemia-associated nuclease 1 gene, which is responsible for DNA repair, and these pathogenic mutations are responsible for progressive renal failure in young adults" (PMID: 38847221). It serves as a mechanistic model for renal fibrosis linked to defective DNA-damage repair.

Key identifiers.

Synonyms / alternative names. Karyomegalic nephropathy; karyomegalic tubulointerstitial nephritis; karyomegalic interstitial nephritis (KIN); FAN1-related KIN. Historically overlapping with descriptions of chronic interstitial nephropathy of unknown aetiology with karyomegaly.

History. First described by Burry in 1974; the term "KIN" was introduced by Mihatsch et al. in 1979 (PMID: 34126972).

Source of information. Data derive largely from aggregated disease-level resources (OMIM, Orphanet) and from individual/small case-series clinical reports and biopsy-based pathology — not from large EHR-based population datasets, reflecting the rarity of the condition (<50–100 reported cases historically).

Section 2 — Etiology

Primary cause (genetic). Biallelic (homozygous or compound heterozygous) loss-of-function variants in FAN1 are the principal Mendelian cause. FAN1 "protein has nuclease activity and acts in DNA interstrand cross-link (ICL) repair within the Fanconi anemia DNA damage response (DDR) pathway" (PMID: 22772369).

Genetic risk factors. The causal locus is 15q13.3. Reported pathogenic variants include nonsense c.2260C>T (p.Arg754Ter) in homozygosity (PMID: 39294548), and frameshift variants c.2616delA (p.Asp873ThrfsTer17) and the novel c.2603delT (p.Leu868ArgfsTer22), both ACMG-classified pathogenic, described in consanguineous Tunisian families (PMID: 34126972). Historical association with HLA-A9/HLA-B35 (and B27/35 haplotype) has been reported as a possible susceptibility background (PMID: 20621605, PMID: 15311851).

Environmental risk factors ("second hits"). Toxic/environmental exposures may trigger or accelerate disease: "additional associations to environmental factors and toxic exposures, such as ochratoxin A, alkylating agents, and heavy metals, which may act as potential triggers of the disease" (PMID: 40529986). Chemotherapeutics (carboplatin, ifosfamide, cisplatin, brentuximab vedotin) and the JAK inhibitor ruxolitinib have induced KIN, including in the absence of FAN1 mutations (PMID: 39543462, PMID: 42139177, PMID: 38955949). Consanguinity is a recognized risk factor for the recessive form.

Protective factors. No established genetic or environmental protective factors are documented. By inference, avoidance of genotoxic exposures (ochratoxin A-contaminated food, nephrotoxic/alkylating drugs) is protective against triggering or accelerating disease in genetically predisposed individuals.

Gene–environment interaction. KIN is a paradigm of gene–environment interaction: an inherited DNA-repair deficiency (FAN1 loss) lowers the threshold at which environmental genotoxins (ochratoxin A, alkylators, heavy metals) cause tubular DNA damage and karyomegaly. Conversely, in individuals without known FAN1 mutations, sufficiently intense genotoxic exposure alone can produce an acquired phenocopy — for ruxolitinib, "we propose that ruxolitinib may induce DNA repair defects in the absence of known genetic predisposition" (PMID: 42139177).

Section 3 — Phenotypes

KIN is clinically indolent early and defined by laboratory/pathological abnormalities more than overt symptoms. "Typical clinical features are asymptomatic progressive renal failure in the third decade of life and recurrent infections, mostly of the upper respiratory tract" (PMID: 7847351).

Cohort quantification (Bhandari et al.): "The age at diagnosis was 9-51 years, median 33 years. Impaired renal function, proteinuria, and haematuria were present in the majority of cases. Non-specific elevated liver enzymes were present in three cases" (of six) (PMID: 12401846). In FAN1-related KIN, "abnormal liver function tests and respiratory involvement are common, in addition to chronic kidney disease" (PMID: 39294548).

Age of onset: adult-onset (childhood-to-adult range 9–51 y; median ~33). Severity: moderate-to-severe (progresses to ESRD). Progression: slowly progressive. Quality-of-life impact: dominated by CKD/ESRD burden (dialysis dependence, transplant morbidity), recurrent infections, and, ultimately, high mortality; formal EQ-5D/SF-36 data are not available for this rare disease.

Section 4 — Genetic / Molecular Information

Causal gene. FAN1 (FANCD2/FANCI-associated nuclease 1), HGNC:29170, OMIM 613534, chromosome 15q13.3. Biallelic loss of function causes KIN (PMID: 22772369).

Pathogenic variant spectrum (representative).

Functional consequence. Loss of function. Wild-type but not KIN-mutant FAN1 cDNA complemented ICL sensitivity in patient cells, confirming pathogenicity (PMID: 22772369). Allele frequencies of the truncating variants are rare in gnomAD (consistent with recessive, largely private/founder mutations in consanguineous pedigrees). Origin is germline; acquired FAN1-negative phenocopies are somatic/toxic in origin.

FAN1 pleiotropy (modifier / other disease roles). - Hereditary colorectal cancer: "We detected FAN1 mutations in approximately 3% of families who met the Amsterdam criteria and had mismatch repair-proficient cancers with no previously associated mutations" (PMID: 26052075). - Repeat-expansion disease modifier: FAN1 is among the strongest DNA-repair modifiers of onset in CAG-repeat disorders; "Non-coding disease-delaying FAN1 variants and coding disease-hastening variants (p.R507H and p.R377W) are known" (PMID: 33579867). Mechanistically FAN1 suppresses somatic repeat expansion and drives contraction via RFC-PCNA-directed nuclease action while inhibiting MutLγ (PMID: 41145416). - 15q13.3 CNVs at the FAN1 locus associate with autism, schizophrenia, and epilepsy.

Epigenetic / chromosomal. No disease-specific DNA-methylation or histone signature is established for KIN. The cellular hallmark is high-ploidy DNA content (endoreduplication) rather than a defined chromosomal translocation.

Section 5 — Environmental Information

Environmental toxins. Ochratoxin A (OTA), a nephrotoxic mycotoxin, is the most-cited environmental agent; markedly elevated OTA levels in blood/urine were found in Tunisian siblings with karyomegalic nephropathy sharing an HLA haplotype, "suggesting (i) a link between OTA and the outcome of this karyomegalic nephropathy, and (ii) the possible involvement of a genetic factor" (PMID: 15311851). OTA-induced nephropathy shows proximal-tubule nuclear abnormalities "with pyknosis, karyorrhexis and karyomegaly" and phenotypic overlap with Balkan Endemic Nephropathy (PMID: 9528187). Heavy metals are also implicated as triggers (PMID: 40529986). CHEBI suggestion: ochratoxin A (CHEBI:7699).

Drug exposures (iatrogenic). Alkylating/DNA-damaging chemotherapeutics — carboplatin, cisplatin, ifosfamide, etoposide — and brentuximab vedotin; also the JAK inhibitor ruxolitinib (PMID: 39543462, PMID: 42139177, PMID: 38955949).

Lifestyle factors. Dietary exposure to OTA-contaminated foodstuffs (cereals, dried goods) is the primary lifestyle-linked risk. No robust association with smoking, alcohol, or exercise.

Infectious agents. None causal. Importantly, viral cytopathic changes (CMV, adenovirus, BK/SV40, EBV) are the key differential to exclude — KIN biopsies are consistently negative for viral inclusions and viral immunohistochemistry (PMID: 30040181).

Section 6 — Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic FAN1 loss-of-function mutation (germline) results in absence/inactivation of the FAN1 structure-specific nuclease. [Demonstrated — PMID: 22772369]
2. Loss of FAN1 impairs two genome-maintenance activities in parallel (branch point):
3. Branch A — ICL repair: reduced unhooking/repair of DNA interstrand cross-links; this activity is FA-pathway-independent and redundant with the 5′–3′ exonuclease SNM1A, so isolated loss is partially buffered. [Demonstrated — PMID: 26980189]
4. Branch B — replication-fork protection: loss of FAN1 recruitment to stalled forks (via its PIP motif/UBZ domain binding ubiquitylated PCNA, and via ubiquitylated FANCD2) leads to failure to restrain fork progression and prevent fork collapse. [Demonstrated — PMID: 29051491, PMID: 26797144]
5. Environmental genotoxins (ochratoxin A, alkylators, heavy metals) act as "second hits" that increase ICLs and replication stress, amplifying the DNA-damage burden the deficient cell cannot resolve. [Inferred from clinical/toxicological association — PMID: 40529986, PMID: 15311851]
6. Unresolved replication stress and DNA damage in renal tubular epithelial cells result in chromosomal instability and activation of DNA-damage-response checkpoints. [Demonstrated in models — PMID: 26797144]
7. Checkpoint activation causes inhibition of mitosis (documented by PCNA/cyclin, Ki-67, p53 marker studies; absent mitotic figures). [Demonstrated — PMID: 7847351, PMID: 12401846]
8. Cells continue DNA synthesis without division → endoreduplication/polyploidy, producing high-DNA-ploidy cells (flow cytometry) that manifest as karyomegaly — the enlarged, hyperchromatic tubular nuclei. [Demonstrated — PMID: 12401846]
9. Damaged/senescent tubular cells drive interstitial inflammation, tubular atrophy, and interstitial fibrosis. [Demonstrated pathologically — PMID: 30040181]
10. Progressive nephron loss results in chronic kidney disease progressing to ESRD; parallel karyomegaly in other organs produces hepatic (elevated LFTs) and respiratory involvement (recurrent infection). [Demonstrated — PMID: 39294548, PMID: 16724656]

ASCII mechanistic model

 FAN1 biallelic LoF (germline)          Environmental genotoxins
        |                                (OTA, alkylators, heavy metals) [2nd hit]
        v                                         |
  loss of nuclease ------------------------------ +
        |                                         |
   +----+-----------------------------+           v
   |                                  |     up ICL burden + replication stress
   v (Branch A)                       v (Branch B)              |
 impaired ICL repair            loss of fork protection <-------+
 (FA-indep., SNM1A-redundant)   (Ub-PCNA/PIP-UBZ; Ub-FANCD2)
   |                                  |
   +----------------+-----------------+
                    v
        chromosomal instability in tubular cells
                    v
        DNA-damage checkpoint -> MITOSIS INHIBITED
                    v
        endoreduplication / polyploidy  ==>  KARYOMEGALY (diagnostic)
                    v
        tubular injury + interstitial inflammation
                    v
        tubular atrophy + INTERSTITIAL FIBROSIS
                    v
        progressive CKD -> ESRD  (+ hepatic & respiratory karyomegaly)

Detail by category

• Molecular pathways: DNA-damage response / Fanconi-anemia-associated ICL repair (FA-independent for FAN1); replication-stress response at stalled forks. Key protein interactions: Ub-PCNA (via FAN1 PIP + UBZ), Ub-FANCD2 (UBZ), and MLH1 (via FAN1 MIP/MIM motifs; PMID: 42409804).
• Cellular processes: cell-cycle dysregulation, mitotic arrest, endoreduplication/polyploidization, senescence, chronic inflammation, fibrogenesis. Suggested GO terms: GO:0036297 (interstrand cross-link repair), GO:0031297 (replication fork processing), GO:0000724 (DSB repair via HR), GO:0007095 (mitotic G2/M checkpoint), GO:0042771 (DDR signal transduction by p53), GO:0090398 (cellular senescence).
• Protein dysfunction: loss of function of a right-hand-shaped, four-domain structure-selective nuclease. FAN1 comprises a UBZ (ubiquitin-binding zinc) domain, SAP DNA-binding domain, TPR-like helical region, and a catalytic virus-type replication-repair nuclease (VRR-Nuc) domain; human FAN1 is monomeric and specific for 5′ flaps. "FAN1 orthologs are monomeric and cleave 5' flap structures in vitro, but not Holliday junctions" (PMID: 24981866); "All four domains of the right-hand-shaped PaFAN1 are involved in DNA recognition, with each domain playing a specific role in bending DNA at the nick" (PMID: 25319828). A dimeric head-to-tail mode has also been crystallized (PMID: 25500724).
• Tissue damage mechanisms: genotoxic/oxidative stress → replication fork collapse → chromosomal instability → fibrosis (renal cortex). FAN1 nuclease-defective knock-in mice are cancer-prone, underscoring the genome-stability role.
• Immune involvement: secondary chronic interstitial inflammation; no primary autoimmunity. Recurrent respiratory infections suggest a functional susceptibility, mechanism undefined.
• Cell types (suggested CL): renal proximal/distal tubular epithelial cell (CL:1000507 kidney tubule cell; CL:1000838 kidney proximal convoluted tubule epithelial cell). Subcellular (GO CC): nucleus (GO:0005634), replication fork (GO:0005657), site of DNA damage (GO:0035861).

Section 7 — Anatomical Structures Affected

• Primary organ: kidney (UBERON:0002113), specifically the renal cortical tubulointerstitium; renal tubular epithelium (UBERON:0004134 nephron tubule epithelium).
• Cell/tissue level: epithelial tissue — proximal and distal tubular epithelial cells bear the karyomegaly; glomeruli and blood vessels may show changes ("Peculiar nuclear changes... involving mainly tubular cells along with glomeruli and blood vessels," PMID: 16724656).
• Subcellular: nucleus (enlargement/hyperchromasia/anisonucleosis) — GO:0005634.
• Secondary / multi-organ: liver (elevated LFTs; hepatic karyomegaly), lung/respiratory tract (recurrent infection). At autopsy, karyomegalic nuclei were found in "brain, thyroid, lung, esophagus, arteries" plus skin, duodenum, liver, and urine cells (PMID: 16724656). UBERON: liver UBERON:0002107; lung UBERON:0002048; thyroid UBERON:0002046; brain UBERON:0000955; esophagus UBERON:0001043; skin UBERON:0002097; duodenum UBERON:0002114.
• Body systems: urinary/renal (primary); hepatobiliary and respiratory (secondary); systemic.
• Lateralization: bilateral (diffuse renal involvement); kidneys are often small/atrophic on imaging.

Section 8 — Temporal Development

• Onset: adult-onset, most classically the third decade (range 9–51 y; median ~33) (PMID: 12401846, PMID: 7847351). Onset pattern is insidious/asymptomatic.
• Progression: chronic, slowly progressive tubulointerstitial fibrosis. Disease course is progressive (not relapsing-remitting), advancing through CKD stages to ESRD, often within several years of diagnosis (in one series, siblings required dialysis 1 and 4 years after diagnosis; PMID: 16724656).
• Duration: chronic and lifelong.
• Remission: none spontaneous; no treatment induces remission. In toxin/drug-associated acquired cases, withdrawal of the offending agent may stabilize (but not reverse) renal function (PMID: 39543462).
• Critical periods / intervention window: early diagnosis (before advanced fibrosis) offers the main opportunity for nephroprotection, genotoxin avoidance, family screening, and transplant planning (PMID: 32220227).

Section 9 — Inheritance and Population

• Inheritance: autosomal recessive (biallelic FAN1 LoF). Consanguinity increases risk; familial clustering is common, with affected siblings frequently reported.
• Penetrance/expressivity: appears high for renal disease in biallelic carriers; expressivity is variable in age of onset and extrarenal (hepatic/respiratory) severity — consistent with modifier and environmental influence.
• Founder effects: private/founder truncating variants reported in consanguineous (e.g., Tunisian) pedigrees (PMID: 34126972).
• Carrier considerations: heterozygous carriers are generally healthy but must NOT serve as living kidney donors — donor-derived/recurrent KIN has occurred in allografts (see Sections 11–12).
• Epidemiology: very rare. "The prevalence of this disease is less than 1% of all biopsies, and its pathogenesis is unclear" (PMID: 34126972). Historically <50–100 reported cases; likely under-diagnosed. Formal population prevalence/incidence rates (per 100,000) are not established.
• Demographics: reported across ethnic groups (Caucasian, North African, East Asian); no strong sex predilection is established (both sexes affected in series). Geographic clustering of the OTA-associated phenocopy overlaps Balkan Endemic Nephropathy regions and North Africa.

Section 10 — Diagnostics

Histopathology (gold standard). Kidney biopsy shows chronic tubulointerstitial nephritis with enlarged, hyperchromatic, pleomorphic tubular epithelial nuclei (karyomegaly), anisonucleosis, interstitial inflammation, tubular atrophy, and interstitial fibrosis; glomeruli are typically normal, and immunofluorescence is negative for immune deposits (PMID: 38847221). A practical threshold for diagnosing karyomegaly (from toxicologic pathology) is nuclei ≥4× normal size (PMID: 30277423). Karyomegaly may also be detectable in urine cells and in skin/duodenal/liver biopsies (PMID: 16724656).

Ancillary pathology. DNA-ploidy flow cytometry demonstrates abnormal high-ploidy populations; proliferation markers Ki-67 and PCNA/cyclin are NOT elevated and mitotic figures are absent — supporting endoreduplication rather than proliferation (PMID: 12401846). Immunohistochemistry for CMV, adenovirus, and SV40/BK is negative — a crucial step to exclude viral cytopathic mimics (PMID: 30040181).

Laboratory. Elevated serum creatinine/reduced eGFR; proteinuria; hematuria; non-specifically elevated liver transaminases (~50%).

Imaging. Small/echogenic kidneys on ultrasound in advanced disease (non-specific); imaging is supportive, not diagnostic.

Genetic testing. Confirmatory. Targeted FAN1 single-gene sequencing (including deletion/duplication analysis) or inclusion of FAN1 on hereditary nephropathy/interstitial-nephritis panels; WES/WGS is highly useful for atypical presentations and was the discovery method (PMID: 22772369). Genetic confirmation enables family screening and donor selection (PMID: 32220227). GTR/GeneReviews/ClinVar are appropriate resources.

Diagnostic criteria & differential. No formal consensus criteria; diagnosis rests on characteristic histology plus FAN1 genotyping. Differential diagnosis: viral tubulointerstitial nephritis (CMV, BK/polyomavirus, adenovirus), drug/chemotherapy-induced karyomegaly, ochratoxin/Balkan endemic nephropathy, and other causes of chronic tubulointerstitial nephritis. KIN can rarely co-occur with glomerular disease (e.g., concurrent IgA nephropathy; PMID: 32387117).

Screening. Cascade genetic/urinary-cytology screening of at-risk relatives; carrier testing of prospective related donors.

Section 11 — Outcome / Prognosis

• Overall course: poor renal prognosis — progressive decline to ESRD requiring dialysis or transplantation. "Karyomegalic interstitial nephritis is a rare progressive renal disease" (PMID: 38681017).
• Mortality: significant. Fatal outcomes reported in native disease (PMID: 16724656). A distinctive post-transplant hazard: "Two patients died soon after transplantation from overwhelming respiratory sepsis" (PMID: 12401846) — likely reflecting systemic disease plus immunosuppression.
• Complications: ESRD, recurrent respiratory infections/sepsis, hepatic dysfunction, and, given FAN1's roles, theoretically increased malignancy risk (established for colorectal cancer in FAN1-mutant families; PMID: 26052075).
• Recovery potential: none for established disease; management slows progression. Transplantation replaces renal function but does not cure the systemic disorder, and KIN can recur or be donor-transmitted in the allograft (PMID: 30040181, PMID: 38681017).
• Prognostic factors: degree of interstitial fibrosis/tubular atrophy at biopsy, baseline eGFR, ongoing genotoxin exposure, and donor carrier status for transplant recipients.

Section 12 — Treatment

There is no disease-specific or curative therapy; management is supportive, preventive, and renal-replacement-based.

Transplant caveat. Living-related donation from heterozygous carriers is hazardous: allograft KIN has arisen from carrier sibling donors, e.g., "underwent kidney transplantation from his sister, and developed the same condition in the graft. Genetic testing of the donor revealed... compound heterozygous mutation of Fanconi anemia-associated nuclease 1" (PMID: 38681017); recurrent/donor-associated KIN also documented at protocol biopsies (PMID: 30040181). Donor FAN1 genotyping is therefore essential (PMID: 32220227).

Advanced/experimental therapeutics. No gene, cell, RNA-based, or targeted therapies exist for KIN; none are in registered trials. Corticosteroids/immunosuppression have no proven benefit and may add infection risk. This is an area of unmet need.

Section 13 — Prevention

• Primary prevention: for at-risk families, genetic counseling and reproductive options (carrier testing, prenatal/preimplantation genetic diagnosis). Population-level reduction of ochratoxin A exposure through food-safety measures (mycotoxin control in cereals/stored foods) is relevant in endemic regions.
• Secondary prevention: early detection via cascade screening of relatives (genetic testing, urinary cytology for karyomegalic cells), enabling early nephroprotection.
• Tertiary prevention: slow CKD progression, treat infections promptly, avoid additional genotoxins, and select genetically cleared kidney donors to prevent allograft disease.
• Genetic counseling: autosomal-recessive recurrence risk (25% for siblings of an affected child of carrier parents); counsel prospective related donors.
• Behavioral/environmental: avoid mold-contaminated foodstuffs; minimize nephrotoxic/alkylating drug exposure where clinically feasible.
• No vaccine/immunization or chemoprophylaxis applies.

Section 14 — Other Species / Natural Disease

• Comparative pathology: renal-tubule karyomegaly is a well-recognized non-clinical (toxicology) finding, "more frequently reported in the rat in response to chemical exposure compared to other laboratory animal species," and much less commonly in mouse, hamster, dog, guinea pig, rabbit, pig, and non-human primate (PMID: 30277423). In humans, "Most instances of renal karyomegaly reported in humans represented cases of the genetic syndrome, karyomegalic interstitial nephritis, known to be caused by a mutation in the FAN1 gene" (PMID: 30277423).
• Veterinary/natural disease: OTA-induced porcine nephropathy features proximal-tubule injury with karyomegaly, providing a naturally occurring animal correlate (PMID: 9528187). No specific companion-animal Mendelian KIN is catalogued (OMIA).
• Orthologs: Fan1 is conserved (mouse Fan1, rat, zebrafish orthologs; NCBI Gene); bacterial/archaeal VRR-Nuc homologs informed structural studies.
• Taxonomy note: the rat is uniquely predisposed to chemically induced tubular karyomegaly, but this "does not necessarily predict a similar alteration in human kidneys" (PMID: 30277423) — a caveat for cross-species risk assessment.
• Zoonotic potential: none (non-infectious).

Section 15 — Model Organisms

Phenotype recapitulation: mouse KO models reproduce the cardinal age-dependent karyomegaly in kidney and liver and organ dysfunction, and often require genotoxic stress to fully manifest KIN — mirroring the human gene–environment ("second hit") model. Limitations: mouse models may require induced genotoxic challenge and may not fully replicate the human respiratory phenotype or the exact tempo of fibrosis; human organoids capture cell-intrinsic mechanisms but lack systemic/immune context. Resources: MGI, IMPC, IMSR (mouse); ZFIN (zebrafish).

Evidence Base — Key Literature

Limitations and Knowledge Gaps

1. Small evidence base. KIN is rare (<50–100 well-characterized cases); most clinical data come from single cases and small series, precluding robust prevalence/incidence, penetrance, sex-ratio, and survival estimates.
2. Fork-protection vs ICL-repair primacy is inferential. The conclusion that stalled-fork protection is the more KIN-relevant FAN1 activity rests on mouse/cell data (PMID: 26797144, PMID: 29051491); direct proof in human renal tubular cells is lacking.
3. Acquired/FAN1-negative KIN is mechanistically unresolved. Whether drug-induced KIN requires a subclinical genetic predisposition or purely reflects toxic DNA damage is unknown (PMID: 39543462).
4. No therapeutics. There are no targeted, gene, or disease-modifying therapies, and no registered trials.
5. Tubular tropism unexplained. Why proximal/distal tubular epithelium (and select extrarenal tissues) are preferentially affected, despite FAN1's ubiquitous expression, is not established.
6. Ontology mapping for the karyomegaly phenotype lacks a precise dedicated HP term.

Proposed Follow-up Experiments / Actions

1. Human tubular cell-specific mechanism: use FAN1-mutant iPSC-kidney organoids (PMID: 37759541) with replication-stress reporters to test whether fork collapse (vs ICL burden) drives endoreduplication/karyomegaly; separate the two functions with domain-specific (PIP/UBZ vs nuclease-dead) mutants.
2. Genotype–phenotype registry: establish an international FAN1-KIN registry to define penetrance, onset variability, extrarenal frequencies, cancer risk, and transplant outcomes.
3. Second-hit dose–response: in Fan1-KO/heterozygous mice, quantify ochratoxin A and alkylator thresholds that precipitate KIN, to inform exposure limits and drug-safety guidance.
4. Biomarker development: validate urinary karyomegalic-cell cytology and DNA-ploidy as non-invasive screening/monitoring tools; explore circulating DNA-damage markers.
5. Donor-screening protocol: formalize FAN1 genotyping of prospective living related donors and post-transplant surveillance biopsy protocols to prevent allograft KIN (PMID: 30040181, PMID: 38681017).
6. Therapeutic exploration: test replication-stress-mitigating or senolytic strategies in models; evaluate whether reducing genotoxic co-exposures slows progression in a prospective cohort.

Report compiled from an autonomous multi-iteration literature investigation (44 papers reviewed; 10 confirmed findings). Evidence types are indicated (human clinical, human genetics, mouse/in vitro model, structural, review). All quoted passages are verbatim from the cited abstracts.